-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
- Verve Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$56.9M, a 8.74% decline year-over-year.
- Verve Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$227M, a 4.45% decline year-over-year.
- Verve Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$223M, a 34.7% decline from 2022.
- Verve Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$166M, a 90.3% decline from 2021.
- Verve Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$87.1M, a 114% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)